Gynecologic Oncologist who is especially interested in robotics, prevention, biomarkers and educating the next generation of providers.
Richmond, VA
Joined March 2014
- Tweets172
- Following149
- Followers310
- Likes619
Stephanie Sullivan retweeted
The latest resource from the 2023-2024 Chemotherapy and Targeted Therapies Subcommittee includes important general guidelines for toxicities commonly involving ocular surface.
SGO members may access this resource for free here:
bit.ly/44eTRpi
Stephanie Sullivan retweeted
EPISODE 152 PRESENTED BY @Pinnacle🚨
@robpizzola and Johnny from @betstamp are joined by @TelemachusModel to discuss what he's been up to, working with @RufusPeabody, facing new challenges, and a whole lot more
➡️ youtu.be/ugSo6WcCHPc
Stephanie Sullivan retweeted
Debulk and Deliver Surgical Course! @SGO_org the future of cancer treatment includes excellent surgical training for gynecologic oncologists. Great way to start #sgo2023 annual meeting @dchimd @StephASullivan @RobertBristow19 @jessiepare
Stephanie Sullivan retweeted
SGO Education Committee coming together with new members for the first time this year to create amazing educational content for cancer providers, great things to come! Check out SGO ConnectEd online #SGOMtg #SGO2022 @SGO_org @StephASullivan
Late breaking is starting!! Always ends up being one of my favorite sessions! So thankful for the inperson and virtual options, I need to go back and watch some missed sessions… What have been other don’t miss sessions so far? #SGOMtg @gynoncjnls @JCohenMD
Stephanie Sullivan retweeted
Bringing Surgery Back at the Debulk and Deliver Master Class! @SGO_org #SGO2022 #SGOMtg #breakbarriers
Sunrise hike (mountain climb?!) with the ridiculously smart Dr. Hacker! Ya’ll- camelback is no joke 😅 #SGOMtg
Amazing distillation by the #bestboss ever. Loving the ‘first immunotherapy’, #HPV vaccine shout out. @drleslie214 #sgomtg #buildingbridges
The debulking course is back!! My former fellow self is totally awestruck with this line up of gyn onc royalty 🤩 @SGO_org #SGO2022 #sgomtg @JCohenMD @LaurenPCobb
Dusting off my Twitter account for first in-person meeting in 2 years!! SGO here we come! @SGO_org @drleslie214
Stephanie Sullivan retweeted
Patients with Isolated tumor cells in Sentinel lymph nodes and otherwise early stage endometrial cancer do not appear to have an increased risk of recurrence and may not benefit from adjuvant therapy. authors.elsevier.com/a/1chBE…
Stephanie Sullivan retweeted
Missed the SGO Allied Health Professionals Meeting? Turnover Talks now have 10-minute recaps of sessions from this year’s meeting, including topics on Clinical Procedures and Sexual Health.
sgo.peachnewmedia.com/store/…
Stephanie Sullivan retweeted
Physical activity following a diagnosis of #endometrialcancer was associated with a reduced risk of reccurrence and death.
Wow. If we had a pill that worked as well as exercise everyone would want it. #gyncsm
ascopubs.org/doi/full/10.120…
Proud of my colleagues at #sgoflyinday ❤️
This year it is virtual but more important than ever to speak with our representatives in Congress and request more funding/support for gynecologic cancers! Honored to be a part of #SGOFlyInDay #SGO @SGO_org #GYnCancerAwarenessMonth
Stephanie Sullivan retweeted
myTIPreport Class Summaries for Milestones and all other evaluation types can now be exported to Excel. This makes ACGME reporting and custom analysis simpler.
Thanks to @bonniekaplan20 for the suggestion!
#MedEd
Stephanie Sullivan retweeted
Don’t have time right now to sit through full-length webinars? Turnover Talks on SGO ConnectEd are a great way to stay current on new data, research and hot topics.
bit.ly/3bvbCFr
Stephanie Sullivan retweeted
Introducing Turnover Talks! Our first 4 discussions in this new series offers quick-bite expert summaries of research presented during the 2020 Annual Meeting on Women's Cancer Webinar Series.
bit.ly/31CrEZP
Stephanie Sullivan retweeted
Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis clincancerres.aacrjournals.o…
